HTT and Huntington disease: demonstrated that both Fer-1 and SRS11-92, specific ferroptosis inhibitors, significantly enhance survival in striatal neurons expressing mutant huntingtin in a dose-dependent manner, providing initial evidence that targeting ferroptosis may offer therapeutic benefits in HD (401).